Research independence: This page contains no affiliate links. Some providers in the dataset have commercial relationships with Care Path Compare and some do not. Affiliate status did not determine the fields, calculations, or findings in this pricing snapshot.
Key findings from the eight-program snapshot
1. Every lowest headline figure needed context
8 of 8 providers (100%) had a lowest observed displayed figure that could be misunderstood without another commercial detail.
The qualifying details were not all the same. They included annual monthly equivalents, a yearly subscription, first-month or starting promotions, product-specific auto-refill pricing, “as low as” language, and a subscription price that may change with the prescription, dose, or refill frequency.
That finding does not mean every provider obscures its price. It means a single headline number was not enough to describe the complete cost structure in any of the eight programs we reviewed.
2. Half published a low figure in a yearly or 12-month context
4 of 8 providers (50%) published a low monthly or monthly-equivalent figure in a yearly or 12-month plan context:
- Gala Health: $179 per month on a yearly compounded subscription.
- HealthRX: $99 per month equivalent on a $1,188 twelve-month compounded semaglutide plan.
- SHED: $159 per month equivalent on a $1,908 twelve-month compounded semaglutide plan.
- Trimi: $99 per month equivalent on a $1,188 annual compounded semaglutide plan.
HealthRX separately also advertised a $99 first month on its true monthly semaglutide plan. That is exactly why the price basis matters: two identical dollar figures can describe different obligations even within one provider.
3. Three providers showed materially different public price presentations
We observed materially different current public price presentations across pages for 3 of 8 providers (37.5%): Gala Health, SHED, and Sprout Health.
Examples included different plan lengths, a category page that did not match a detailed product page, and a homepage starting figure that differed from the standard monthly figure on a dedicated program page.
We did not automatically label those differences errors. Marketing page, plan length, promotion, product, or update timing can explain a different number. We recorded the difference and treated checkout terms as the point that needs confirmation.
4. “$99 per month” described three different commercial structures
Three providers in the snapshot displayed a $99 semaglutide-related figure, but the number did not mean the same thing:
| Provider | What the $99 figure represented | What it did not automatically mean |
|---|---|---|
| HealthRX | A new-patient first month on the monthly semaglutide plan and a separate $99 monthly equivalent on a $1,188 twelve-month plan | That every month is billed at $99 |
| Strut Health | A product-specific auto-refill starting price for oral compounded semaglutide | A universal Strut weight-loss program price |
| Trimi | A $99 monthly equivalent created by a $1,188 annual semaglutide charge | A $99 month-to-month plan |
This is one of the clearest reasons to compare price type, not just price amount.
The August 2026 dataset
The field called lowest observed displayed figure is the smallest monthly or monthly-equivalent dollar figure we found in the provider source set used for this snapshot. It is intentionally not labeled “true monthly cost.”
| Provider | Lowest observed displayed figure | Price basis | Clear one-month/month-to-month reference | Pricing note |
|---|---|---|---|---|
| Gala Health | $179 | Starting monthly figure on yearly compounded subscription | Not clearly established in this source set | Another public page showed $199/month with a three-month plan |
| HealthRX | $99 | First-month promotion and separate 12-month monthly equivalent | $190 | $1,188 twelve-month semaglutide total also equals $99/month |
| SHED | $159 | 12-month monthly equivalent | $199 | $1,908 twelve-month semaglutide total; payment may be full or installments at checkout |
| SkinnyRx | $199 | “As low as” compounded semaglutide starting price | Not clearly established | Conditions behind the lowest figure were not fully synchronized publicly |
| Sprout Health | $149 | Homepage compounded semaglutide starting price | $299 | Main GLP-1 page showed a higher standard monthly figure |
| Strut Health | $99 | Product-specific auto-refill starting price | Not used as a universal reference | Applies to oral compounded semaglutide, not every Strut pathway |
| Trimi | $99 | 12-month monthly equivalent | $175 | $1,188 annual semaglutide charge is paid upfront |
| Willow | $299 | Compounded semaglutide starting price | Not treated as fixed | Terms say subscription price may change with prescription, dose, or refill frequency |
Descriptive statistic only: the eight lowest observed displayed figures are $99, $99, $99, $149, $159, $179, $199, and $299. Their median is $154. That median describes advertised figures in this dataset; it is not an estimate of what an individual will pay for GLP-1 treatment.
Why we did not rank the cheapest provider
The dataset mixes different commercial structures because that is the consumer problem we are measuring.
A price can represent:
- a true one-month charge;
- a first-month promotion;
- a monthly equivalent calculated from a prepaid plan;
- a starting price that may vary;
- one formulation within a larger program;
- or an auto-refill price that depends on staying in that product pathway.
Ranking those numbers from cheapest to most expensive would create false precision. The more useful comparison is whether a reader can identify the amount due today, recurring charge, plan commitment, included services, renewal amount, and refund cutoff before paying.
Methodology
Provider set
This snapshot covers eight online GLP-1 programs already included in Care Path Compare’s current total-cost research: Gala Health, HealthRX, SHED, SkinnyRx, Sprout Health, Strut Health, Trimi, and Willow.
The sample is not intended to represent every U.S. telehealth weight-loss company. It is a tracked research set, not a market-share panel or randomized sample.
Observation window
Commercial source checks used for this dataset occurred from July 29 through August 8, 2026, with Gala source work beginning July 15 and later incorporated into the current comparison. Provider prices and policies can change after the observation date.
Standardized fields
For each provider, we recorded:
- The lowest observed displayed monthly or monthly-equivalent dollar figure in the source set.
- The type of price: starting price, promotion, auto-refill price, monthly equivalent, or other presentation.
- The condition needed to interpret that figure.
- A clear one-month or month-to-month reference when the provider published one in a directly usable form.
- A plan total when the qualifying multi-month total was explicitly available.
- Whether materially different public price presentations were observed across the reviewed pages.
- The commercial verification date and official source URL.
We did not infer missing plan totals, renewal prices, dose pricing, or checkout charges when the provider source set did not establish them clearly.
Calculations
The $154 median is the ordinary median of the eight recorded lowest observed displayed figures. Percentages use the eight-provider snapshot as the denominator. No weighting is applied for provider size, traffic, prescription volume, medication type, or affiliate economics.
Download and cite the data
Download the full CSV dataset
For reporting, research, or charts, you may cite or summarize these findings with attribution to Care Path Compare, GLP-1 Telehealth Pricing Index, August 2026 and a link to this page. Please preserve the qualifiers around starting prices, monthly equivalents, and unlike formulations.
A concise citation-ready summary is:
Care Path Compare’s August 2026 snapshot of eight online GLP-1 programs found that all eight lowest observed displayed price figures required at least one commercial qualifier. The figures ranged from $99 to $299, with a descriptive median of $154, but they were not directly comparable actual monthly treatment costs.
For questions about the methodology or dataset, use our contact page.
Limitations
This analysis is a commercial-pricing snapshot, not medical research and not a clinical comparison.
- The sample includes eight tracked telehealth programs, not the entire market.
- Provider pages can change after the observation date.
- A displayed price does not establish eligibility, prescribing, pharmacy fulfillment, medication availability, insurance coverage, or the final checkout amount.
- Compounded products in the dataset are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality.
- Different formulations and medications should not be treated as clinically interchangeable because their prices appear in the same commercial dataset.
For a consumer-focused cost comparison, see our online GLP-1 program total-cost guide. For renewal and refund fine print, see our cancellation, renewal, and refund policy guide.